Trial Profile
A Study to Compare the Safety and Efficacy of Two Ranibizumab Dosing Regimens in a Turkish Cohort of Patients With Choroidal Neovascularization Secondary to AMD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 29 Apr 2016 New trial record